Since 2010, the BioImaging Center Lille-Nord of France (BICeL) has provided improved support for research in the Region thanks to an organisation that brings together the cellular and tissue imaging platforms of the university hospital campus (CHRU-Lille2), the University of Science and Technology of Lille 1 (campus Lille 1) and the Pasteur and Biology Institutes of Lille (Pasteur campus).

This organisation, thanks to the dedication of the staff on the three sites, has received national recognition by obtaining the GIS-IBISA certification in 2010 and a PIA-EquipEx ImagInEx BioMed (Rank 1) in 2011 backed by the European fund for regional development ("Fond Européen de Développement Régional") (FEDER) implemented by the Regional Council of the Nord Pas-de-Calais.

The Transcriptomics and Applied Genomics (TAG) was created in 2000 by the Institut Pasteur de Lille with the support of the European InterReg program. It joined the Center for Infection and Immunity (CIIL) in 2010. It received the IBISA label in 2010 as part of the platform group LIGAN. TAG is developing high-throughput genomic solutions and applications using micro-array and high-speed sequencing technologies. These applications are offered to the scientific community in response to collaboration proposals or in the form of services. TAG is also developing analytic and bioinformatics tools and solutions in relation with the proposed genomic applications. TAG is part of the Lille Bioinformatics platform, Bilille.

Modified Peptide and Proteomics Platform Plateau (P3M)

The Modified Peptide and Proteomics Platform Plateau (P3M) provides the research teams of the LabEx ParaFrap, the Lille immunity and infection centre (CIIL) and, more generally, the national and international public and private laboratories with the most recent cutting-edge technologies for analysing proteomics and characterising proteins. The platform was created at the instigation of the LabEx ParaFrap ("Alliance Française contre les Maladies Parasitaires" - French Alliance against parasitic diseases) thanks to the financial support of the PIA and the FEDER. It is attached to the CIIL (INSERM U1019 - CNRS UMR 8204), is managed by Institut Pasteur de Lille, with the support of the CNRS and is incorporated within the coordination of the Lille biology and health platforms (Lille University, INSERM, CNRS, IPL).

Contact : Jean Michel SALIOU



The Sub-Saharan Clinical Research (RC2S) team  is supported by the Pasteur Institute of Lille in the frame of the international network of Pasteur Institutes (RIIP) with the purpose to provide a health core facility towards the development of human clinical trials in Senegal. The RC2S dedicates its activities to the coordination of clinical studies in West Africa on behalf of CIIL teams and regional partners. The team also coordinates extensive medical research programs in Africa for foreign organizations. Its activities range from protocol writing, relations with ethics committees and African authorities, logistical preparation of the study, coordination in the field, management of data, and analyzes of results. Thus, our Lille platform is the strategic antenna of the Centre de Recherche Biomédicale EPLS (CRB-EPLS), located in Saint Louis of Senegal and operating throughout the River Basin. The CRB-EPLS is certified as a clinical research platform by Inserm (France), Fiocruz Foundation (Brazil), National Institute of Health (USA), National Science Foundation (USA), B&M. Gates Foundation (USA), and by the World Health Organization (WHO). In addition to coordinating clinical, epidemiological and public health studies carried out in Senegal, the RC2S team has been focusing its research for the past five years on the study of risk factors influencing the immune response to humans infections or mandatory vaccines in Africa, the nutritional status of children or the emergence of chronic non communicable diseases in urban areas. We currently manage a clinical phase 2 trial for the development of a vaccine candidate against human schistosomiasis and an ecological project for reducing transmission of this parasitic disease.